Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Philippos Costa, MD
Sarcoma, Medical Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine
Titles
- Assistant Professor of Medicine (Medical Oncology and Hematology)
- Scientific-Advisor, Medical Oncology, Associação Tumor Desmoide Brasil
Education & Training
- MSYale, Internal Medicine (2025)
- Internal MedicineUniversity of Miami (2022)
- Internal MedicineUniversidade Federal de Uberlândia: (2018)
- MDUniversidade Federal do Vale do São Francisco, Medicine (2016)
- ResidencyJackson Memorial Hospital
- FellowshipYale University School of Medicine
Languages Spoken
- English
- Português (Portuguese)
- Español (Spanish)
Additional Information
Honors & Recognitions
- The Vanessa Blumer Research Scholar Award: (2022)
Board Certifications
- AB of Internal Medicine, Internal Medicine (2022)
Professional Service
- Managed Health Care (2022 - Present): Featured in magazine article entitled “Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy” based on the work “Prevalence of Targetable Mutations in Black Patients"
- GIST Journal (2021 - Present): Reviewer
- Connective Tissue Oncology Society (CTOS) (2019 - Present): Member
- American Society of Clinical Oncology (ASCO) (2018 - Present): Member
- American College of Physicians (ACP) (2018 - Present): Member
- Sociedade Brasileira de Oncologia Clínica (SBOC) (2018 - Present): Member
Publications
- Wang J, Perry C, Frey A, Fei Y, Costa P, Ghadermarzi S, Levine D, Ishizuka J. 907 Midkine suppresses interferon-driven antigen presentation and dendritic-cell activation in neuroendocrine tumors. 2025, a1027-a1027. DOI: 10.1136/jitc-2025-sitc2025.0907.
- Raja A, Costa P, Junejo M. Kaposi sarcoma incidence and mortality trends and disparities in the United States. Infectious Agents And Cancer 2025, 20: 80. PMID: 41189007, PMCID: PMC12584236, DOI: 10.1186/s13027-025-00710-x.
- Pfaff M, Costa P, Tang H, Sailo B, Sharma A, Ahuja N. Decoding the Epigenome: Comparative Analysis of Uterine Leiomyosarcoma and Leiomyoma. Cancers 2025, 17: 2610. PMID: 40867239, PMCID: PMC12384543, DOI: 10.3390/cancers17162610.
- Costa P, Hardy N, LoRusso P. PALB2 c.3106G>C (p.Val1036Leu) in a familial cancer setting suggesting potential pathogenicity. BMJ Case Reports 2025, 18: e266362. PMID: 40750108, DOI: 10.1136/bcr-2025-266362.
- Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire A, Coelho P, Costa P, D’Amato G, Jonczak E, Trent J, Montgomery E, Lombard D, Rosenberg A, Dhir A. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers 2025, 17: 1962. PMID: 40563612, PMCID: PMC12191036, DOI: 10.3390/cancers17121962.
- Fei Y, Costa P, Junejo M, Li M, Perry C, Damsky W, Ishizuka J. Transcriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23526.
- Costa P, Hafez N, Pilat M, Kalyan A, Azad N, Gore S, Shields A, Al Hallak M, Jin N, Malalur P, Hays J, Rodon Ahnert J, Schalper K, LoRusso P. A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors. Journal Of Clinical Oncology 2025, 43: 3089-3089. DOI: 10.1200/jco.2025.43.16_suppl.3089.
- A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.Costa P, Pilat M, Rodon Ahnert J, Burgess M, Tinoco G, Close J, Groisberg R, Subbiah V, Powers B, Haddox C, Grilley-Olson J, Keedy V, Li J, Ivy S, Patel A, Shapiro G, Ishizuka J, Schalper K, LoRusso P. A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. Journal Of Clinical Oncology 2025, 43: 3087-3087. DOI: 10.1200/jco.2025.43.16_suppl.3087.
- Yi I, Gomes P, Hardy N, Rose B, Yu-Cherng C, Bialick S, Jonczak E, D'Amato G, Deshpande H, Carmagnani Pestana R, David B, Trent J, Campos F, Costa P. Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation. Journal Of Clinical Oncology 2025, 43: 11562-11562. DOI: 10.1200/jco.2025.43.16_suppl.11562.
- Hardy N, Frej K, Nkansah R, Olino K, Deshpande H, Ma X, Trent J, Costa P. Twenty‐five years without progress: The enduring challenge of soft tissue sarcomas. Cancer 2025, 131: e35906. PMID: 40396557, DOI: 10.1002/cncr.35906.
- Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.
- Costa P, Menezes C, David B, Garofalo G, Barbieri L, Campos F. Enhancing rare cancer care in developing countries through patient advocacy: insights from the Desmoid Tumor Brazilian Association. Therapeutic Advances In Medical Oncology 2025, 17: 17588359241309827. PMID: 39801613, PMCID: PMC11719451, DOI: 10.1177/17588359241309827.
- Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.
- Noujaim J, Gupta A, Holloway C, Saleh R, Srikanthan A, Lemieux C, Soroka H, Tibout P, Turcotte R, Feng X, Abdul Razak A, Costa P. Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]. European Journal Of Cancer 2024, 208: 114221. PMID: 38981738, DOI: 10.1016/j.ejca.2024.114221.
- Noujaim J, Gupta A, Holloway C, Saleh R, Srikanthan A, Lemieux C, Soroka H, Tibout P, Turcotte R, Feng X, Abdul Razak A, Costa P. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study. European Journal Of Cancer 2024, 205: 114119. PMID: 38759389, DOI: 10.1016/j.ejca.2024.114119.
- Chaves C, Costa P, Barbieri L, David B, de Mello C, Campos F, Mounssef G. 45P The patient voices: Revealing the challenges faced by persons with desmoid tumors in a middle-income country. ESMO Open 2024, 9: 102434. DOI: 10.1016/j.esmoop.2024.102434.
- Costa P, Tse D, Benedetto P. Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. The Oncologist 2024, 29: 263-269. PMID: 38227581, PMCID: PMC10911902, DOI: 10.1093/oncolo/oyad346.
- Karigyo C, Pessoa B, Nicacio S, Terwilliger E, Costa P, dos Santos P, Ernani V, Seetharam M, Murakami A, Batalini F. Cardiac Tumors: Review. Brazilian Journal Of Cardiovascular Surgery 2024, 39: e20230405. PMID: 39038269, PMCID: PMC11262154, DOI: 10.21470/1678-9741-2023-0405.
- Souza F, D’Amato G, Jonczak E, Costa P, Trent J, Rosenberg A, Yechieli R, Temple H, Pattany P, Subhawong T. MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results. Frontiers In Oncology 2023, 13: 1286807. PMID: 38188297, PMCID: PMC10766853, DOI: 10.3389/fonc.2023.1286807.
- O’Neil D, Martei Y, Crew K, Castillo B, Costa P, Lim T, Michel A, Rubin E, Goel N, Hurley J, Lopes G, Antoni M. Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open 2023, 6: e2346223. PMID: 38051529, PMCID: PMC10698616, DOI: 10.1001/jamanetworkopen.2023.46223.
- Yan C, Costa P, Wu Y. Acute pancreatitis from a delayed haemolytic transfusion reaction. Transfusion Medicine 2022, 32: 522-524. PMID: 36056461, DOI: 10.1111/tme.12912.
- Liu S, Miramontes B, Souza F, Costa P, Subhawong T, Espejo-Freire A, Jonczak E, D'Amato G, Venkat S. Cryoablation as an effective treatment for desmoid tumors: A single-institution case series. Journal Of Clinical Oncology 2022, 40: e23543-e23543. DOI: 10.1200/jco.2022.40.16_suppl.e23543.
- Costa P, Arora A, Tan H, Fernandez Y, Campoverde L, Coelho P, Bialick S, Espejo-Freire A, Jonczak E, D'Amato G, Subhawong T, Trent J. Comparative effectiveness of systemic treatments in desmoid tumors. Journal Of Clinical Oncology 2022, 40: e23534-e23534. DOI: 10.1200/jco.2022.40.16_suppl.e23534.
- Coelho P, Seldon C, Vazquez C, Yang B, Rose B, Bialick S, Espejo-Freire A, Costa P, D'Amato G, Trent J, Yechieli R, Jonczak E. Complete pathological response after neoadjuvant treatment in soft tissue sarcoma: A single-institution experience. Journal Of Clinical Oncology 2022, 40: e23526-e23526. DOI: 10.1200/jco.2022.40.16_suppl.e23526.
- Espejo-Freire A, Campoverde L, Kropotova Y, Statz-Geary K, Costa P, Coelho P, Bialick S, D'Amato G, Jonczak E, Trent J, Dhir A. Heterogeneity in treatment regimens for AYA bone sarcomas: A comparison of outcomes at a single sarcoma center. Journal Of Clinical Oncology 2022, 40: e23508-e23508. DOI: 10.1200/jco.2022.40.16_suppl.e23508.
- Coelho P, Bialick S, Rose B, Elliot A, Walker P, Abraham J, Leu K, von Mehren M, Espejo-Freire A, Costa P, D'Amato G, Rosenberg A, Trent J, Dhir A. DNA damage response pathways in synovial sarcoma. Journal Of Clinical Oncology 2022, 40: 11580-11580. DOI: 10.1200/jco.2022.40.16_suppl.11580.
- Bialick S, Statz-Geary K, Elliott A, Abraham J, Walker P, Espejo-Freire A, Coelho P, Costa P, Leu K, von Mehren M, D'Amato G, Jonczak E, Trent J, Rosenberg A, Dhir A. Pan-sarcoma analysis of DNA damage response pathway alterations and deficiency. Journal Of Clinical Oncology 2022, 40: 11548-11548. DOI: 10.1200/jco.2022.40.16_suppl.11548.
- Bialick S, Rose B, Espejo-Freire A, Coelho P, Costa P, Campoverde L, Drusbosky L, Arshad J, Serrano C, George S, Bauer S, Goel N, Venkat S, Dhir A, Jonczak E, D'Amato G, Trent J. KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor. Journal Of Clinical Oncology 2022, 40: 11514-11514. DOI: 10.1200/jco.2022.40.16_suppl.11514.
- Minjares R, Costa P, Montoya-Cerrillo D, Aguirre L. Primary jejunal gastrointestinal stromal tumor in a patient with phakomatosis: a case report of an uncommon source of massive gastrointestinal hemorrhage. Gastrointestinal Stromal Tumor 2022, 5: 2-2. DOI: 10.21037/gist-21-13.
- Barreto-Coelho P, Rosenberg A, Subhawong T, Costa P, Espejo-Freire A, Bialick S, Jonczak E, Trent J, D'Amato G. Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precision Oncology 2022, 6: e2100336. PMID: 35108034, DOI: 10.1200/po.21.00336.
- Minjares RO, Aguirre LE, Costa PA, Montoya-Cerrillo DM, Goldberg DS. Primary Jejunal GIST in a Patient with Phakomatosis: An Atypical Source of Massive Gastrointestinal Hemorrhage Associated with RASopathy. Gastrointestinal Stromal Tumor 2022. doi: 10.21037/gist-21-13
- Freire A, Elliott A, Rosenberg A, Costa P, Barreto-Coelho P, Jonczak E, D’Amato G, Subhawong T, Arshad J, Diaz-Perez J, Korn W, Oberley M, Magee D, Dizon D, von Mehren M, Khushman M, Hussein A, Leu K, Trent J. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. Cancers 2021, 13: 4816. PMID: 34638300, PMCID: PMC8507700, DOI: 10.3390/cancers13194816.
- Costa P, Espejo-Freire A, Fan K, Albini T, Pongas G. Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate. Leukemia & Lymphoma 2021, 63: 239-242. PMID: 34514943, DOI: 10.1080/10428194.2021.1978090.
- Costa P, Marbin S, Costa B, Espejo‐Freire A, Saul E, Barreto‐Coelho P, Allen A, Hakim M, Goel N, D’Amato G, Subhawong T, Trent J. A nonrandom association of breast implants and the formation of desmoid tumors. The Breast Journal 2021, 27: 768-775. PMID: 34453383, DOI: 10.1111/tbj.14276.
- Arshad J, Costa P, Barreto-Coelho P, Valdes B, Trent J. Immunotherapy Strategies for Gastrointestinal Stromal Tumor. Cancers 2021, 13: 3525. PMID: 34298737, PMCID: PMC8306810, DOI: 10.3390/cancers13143525.
- Coelho P, Costa P, Freire A, Kwon D, Jonczak E, D'Amato G, Trent J. Outcomes of metastatic synovial sarcoma with doxorubicin, pazopanib, and ifosfamide therapy. Journal Of Clinical Oncology 2021, 39: e23552-e23552. DOI: 10.1200/jco.2021.39.15_suppl.e23552.
- Hana C, Costa P, D'Amato G, Trent J. Differential risk factors between uterine sarcomas and malignant mixed Müllerian tumors. Journal Of Clinical Oncology 2021, 39: e23551-e23551. DOI: 10.1200/jco.2021.39.15_suppl.e23551.
- Dawar R, Gawri K, Rodriguez E, Kwon D, Basher F, Costa P, Khan K, Torres T, Ikpeazu C, Lopes G. Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy. Journal Of Clinical Oncology 2021, 39: e21219-e21219. DOI: 10.1200/jco.2021.39.15_suppl.e21219.
- Rodriguez E, Dawar R, Basher F, Costa P, Torres T, Nguyen D, Villamizar N, Lopes G. Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice. Journal Of Clinical Oncology 2021, 39: e20507-e20507. DOI: 10.1200/jco.2021.39.15_suppl.e20507.
- Costa P, Gallegos J, Pongas G. Outcomes in peripheral T-cell lymphomas: An analysis of patients treated at a single academic institution. Journal Of Clinical Oncology 2021, 39: e19524-e19524. DOI: 10.1200/jco.2021.39.15_suppl.e19524.
- Alasfour M, Alawadi S, AlMojel M, Costa P, Coelho P, Plate T, Ahn S, Lopes G. Clinical outcomes of cancer patients with COVID-19: A systematic review and meta-analysis. Journal Of Clinical Oncology 2021, 39: e18600-e18600. DOI: 10.1200/jco.2021.39.15_suppl.e18600.
- Costa P, Pelaez D, Tse D, Benedetto P. Neoadjuvant intraarterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma: A 33-year single-institution experience. Journal Of Clinical Oncology 2021, 39: e18051-e18051. DOI: 10.1200/jco.2021.39.15_suppl.e18051.
- Costa P, Saul E, Paul Y, Iyer S, da Silva L, Tamariz L, Lopes G. Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice 2021, 17: e629-e636. PMID: 33974815, DOI: 10.1200/op.20.00961.
- Costa P, Costa B, Rozenbaum G, Barreto-Coelho P. Anti-Ma paraneoplastic opsoclonus–myoclonus syndrome. BMJ Case Reports 2021, 14: e243136. PMID: 33975854, PMCID: PMC8117984, DOI: 10.1136/bcr-2021-243136.
- Costa P, Hana C, Balaji N, Skryd A, Valdes B, Minjares R, Barreto-Coelho P, Espejo-Freire A, Hakim M, Jonczak E, Subhawong T, Livingstone A, Trent J, D'Amato G. Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases. Gastrointestinal Stromal Tumor 2021, 4: 1-1. DOI: 10.21037/gist-21-1.
- Barreto-Coelho P, Costa P, Espejo-Freire A, Jonczak E, D’Amato G, Trent J. Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances. TouchREVIEWS In Oncology & Haematology 2021, 17: 18. DOI: 10.17925/ohr.2021.17.1.18.
- Costa PA, Hana CKA, Chakravarthy N, Skryd AF, Valdes BN, Barreto-Coelho P, Minjares RO, Espejo-Freire A, Hakim MO, Jonczak E, Subhawong T, Livingstone A, Trent JC, D’Amato GZ. Dose Escalation of Ripretinib can Lead to Response in Advanced Gastrointestinal Stromal Tumors Refractory to the Standard Dose: A Report of Two Cases. Gastrointestinal Stromal Tumor. DOI: 10.21037/gist-21-1
- Barreto-Coelho P., Costa PA, Espejo-Freire A., Jonczak E., D’Amato G., Trent J.C. Advanced and Metastatic GIST: Review of Current Knowledge and Latest Advances 2021; touchONCOLOGY.
- Costa P, Costa B, Milikowski C, St Onge J. Acute generalised exanthematous pustulosis associated with shock. BMJ Case Reports 2020, 13: e235846. PMID: 33127730, PMCID: PMC7604797, DOI: 10.1136/bcr-2020-235846.
- Costa P, Needelman B, Tjendra Y, Hoffman J. High-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a cervical mass. BMJ Case Reports 2020, 13: e235451. PMID: 32843454, PMCID: PMC7449310, DOI: 10.1136/bcr-2020-235451.
- Espejo Freire A, Costa P, Alasfour M, Akgun Y, Rosenberg A, Diaz-Perez J, Kwon D, Subhawong T, Arshad J, Trent J. Clinical behavior and treatment outcomes in angiosarcoma: A 10-year retrospective review. Journal Of Clinical Oncology 2020, 38: e23555-e23555. DOI: 10.1200/jco.2020.38.15_suppl.e23555.
- Espejo Freire A, Elliott A, Akgun Y, Costa P, Alasfour M, Rosenberg A, Diaz-Perez J, Subhawong T, Arshad J, Korn W, Dizon D, von Mehren M, Khushman M, Hussein A, Leu K, Trent J. Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients. Journal Of Clinical Oncology 2020, 38: 11545-11545. DOI: 10.1200/jco.2020.38.15_suppl.11545.
- Ferreira Junior E, Costa P, Freire Golveia Silveira L, Pertile Salvioni N, Loureiro B, Lodi Peres S, Pereira T. Transhiatal esophagectomy with gastric pull-up, pyloric exclusion and Roux-en-Y gastroenterostomy for the management of esophageal caustic injury. International Journal Of Surgery Case Reports 2019, 56: 66-69. PMID: 30831510, PMCID: PMC6403175, DOI: 10.1016/j.ijscr.2019.02.006.
- Ferreira Junior E, Costa P, Silveira L, Almeida L, Salvioni N, Loureiro B. Giant bullous emphysema mistaken for traumatic pneumothorax. International Journal Of Surgery Case Reports 2019, 56: 50-54. PMID: 30826593, PMCID: PMC6402233, DOI: 10.1016/j.ijscr.2019.02.005.
- Costa P, Reis W, Loureiro B, Ferreira E, Rocha J, Alencar K. Tumor Desmoplásico de Pequenas Células Redondas: Relato de Caso. Revista Brasileira De Cancerologia 2018, 64: 575-579. DOI: 10.32635/2176-9745.rbc.2018v64n4.208.
- Ferreira Junior E, Apolinario Costa P, Freire Golveia Silveira L, Valois Vieira R, Lima Martins Soares H, Menon Loureiro B, Pertile Salvioni N, Coelho Ferreira Rocha J. Localized pancreatic Castleman disease presenting with extrahepatic dilatation of bile ducts: A case report and review of published cases. International Journal Of Surgery Case Reports 2018, 54: 28-33. PMID: 30513495, PMCID: PMC6279997, DOI: 10.1016/j.ijscr.2018.11.006.
- Desmoplastic small-round-cell tumorCosta PA, Reis WG, Loureiro BM, Ferreira Junior EG, Rocha JRCF, Alencar KMSA. Revista Brasileira De Cancerologia, 2018, Dec; 64(4), 573-577.
Departments and Programs
Locations
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Titles
- Assistant Professor of Medicine (Medical Oncology and Hematology)
- Scientific-Advisor, Medical Oncology, Associação Tumor Desmoide Brasil
Education & Training
- MSYale, Internal Medicine (2025)
- Internal MedicineUniversity of Miami (2022)
- Internal MedicineUniversidade Federal de Uberlândia: (2018)
- MDUniversidade Federal do Vale do São Francisco, Medicine (2016)
- ResidencyJackson Memorial Hospital
- FellowshipYale University School of Medicine
Languages Spoken
- English
- Português (Portuguese)
- Español (Spanish)
Additional Information
Honors & Recognitions
- The Vanessa Blumer Research Scholar Award: (2022)
Board Certifications
- AB of Internal Medicine, Internal Medicine (2022)
Professional Service
- Managed Health Care (2022 - Present): Featured in magazine article entitled “Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy” based on the work “Prevalence of Targetable Mutations in Black Patients"
- GIST Journal (2021 - Present): Reviewer
- Connective Tissue Oncology Society (CTOS) (2019 - Present): Member
- American Society of Clinical Oncology (ASCO) (2018 - Present): Member
- American College of Physicians (ACP) (2018 - Present): Member
- Sociedade Brasileira de Oncologia Clínica (SBOC) (2018 - Present): Member
Publications
- Wang J, Perry C, Frey A, Fei Y, Costa P, Ghadermarzi S, Levine D, Ishizuka J. 907 Midkine suppresses interferon-driven antigen presentation and dendritic-cell activation in neuroendocrine tumors. 2025, a1027-a1027. DOI: 10.1136/jitc-2025-sitc2025.0907.
- Raja A, Costa P, Junejo M. Kaposi sarcoma incidence and mortality trends and disparities in the United States. Infectious Agents And Cancer 2025, 20: 80. PMID: 41189007, PMCID: PMC12584236, DOI: 10.1186/s13027-025-00710-x.
- Pfaff M, Costa P, Tang H, Sailo B, Sharma A, Ahuja N. Decoding the Epigenome: Comparative Analysis of Uterine Leiomyosarcoma and Leiomyoma. Cancers 2025, 17: 2610. PMID: 40867239, PMCID: PMC12384543, DOI: 10.3390/cancers17162610.
- Costa P, Hardy N, LoRusso P. PALB2 c.3106G>C (p.Val1036Leu) in a familial cancer setting suggesting potential pathogenicity. BMJ Case Reports 2025, 18: e266362. PMID: 40750108, DOI: 10.1136/bcr-2025-266362.
- Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire A, Coelho P, Costa P, D’Amato G, Jonczak E, Trent J, Montgomery E, Lombard D, Rosenberg A, Dhir A. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers 2025, 17: 1962. PMID: 40563612, PMCID: PMC12191036, DOI: 10.3390/cancers17121962.
- Fei Y, Costa P, Junejo M, Li M, Perry C, Damsky W, Ishizuka J. Transcriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23526.
- Costa P, Hafez N, Pilat M, Kalyan A, Azad N, Gore S, Shields A, Al Hallak M, Jin N, Malalur P, Hays J, Rodon Ahnert J, Schalper K, LoRusso P. A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors. Journal Of Clinical Oncology 2025, 43: 3089-3089. DOI: 10.1200/jco.2025.43.16_suppl.3089.
- A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.Costa P, Pilat M, Rodon Ahnert J, Burgess M, Tinoco G, Close J, Groisberg R, Subbiah V, Powers B, Haddox C, Grilley-Olson J, Keedy V, Li J, Ivy S, Patel A, Shapiro G, Ishizuka J, Schalper K, LoRusso P. A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. Journal Of Clinical Oncology 2025, 43: 3087-3087. DOI: 10.1200/jco.2025.43.16_suppl.3087.
- Yi I, Gomes P, Hardy N, Rose B, Yu-Cherng C, Bialick S, Jonczak E, D'Amato G, Deshpande H, Carmagnani Pestana R, David B, Trent J, Campos F, Costa P. Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation. Journal Of Clinical Oncology 2025, 43: 11562-11562. DOI: 10.1200/jco.2025.43.16_suppl.11562.
- Hardy N, Frej K, Nkansah R, Olino K, Deshpande H, Ma X, Trent J, Costa P. Twenty‐five years without progress: The enduring challenge of soft tissue sarcomas. Cancer 2025, 131: e35906. PMID: 40396557, DOI: 10.1002/cncr.35906.
- Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.
- Costa P, Menezes C, David B, Garofalo G, Barbieri L, Campos F. Enhancing rare cancer care in developing countries through patient advocacy: insights from the Desmoid Tumor Brazilian Association. Therapeutic Advances In Medical Oncology 2025, 17: 17588359241309827. PMID: 39801613, PMCID: PMC11719451, DOI: 10.1177/17588359241309827.
- Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.
- Noujaim J, Gupta A, Holloway C, Saleh R, Srikanthan A, Lemieux C, Soroka H, Tibout P, Turcotte R, Feng X, Abdul Razak A, Costa P. Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]. European Journal Of Cancer 2024, 208: 114221. PMID: 38981738, DOI: 10.1016/j.ejca.2024.114221.
- Noujaim J, Gupta A, Holloway C, Saleh R, Srikanthan A, Lemieux C, Soroka H, Tibout P, Turcotte R, Feng X, Abdul Razak A, Costa P. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study. European Journal Of Cancer 2024, 205: 114119. PMID: 38759389, DOI: 10.1016/j.ejca.2024.114119.
- Chaves C, Costa P, Barbieri L, David B, de Mello C, Campos F, Mounssef G. 45P The patient voices: Revealing the challenges faced by persons with desmoid tumors in a middle-income country. ESMO Open 2024, 9: 102434. DOI: 10.1016/j.esmoop.2024.102434.
- Costa P, Tse D, Benedetto P. Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. The Oncologist 2024, 29: 263-269. PMID: 38227581, PMCID: PMC10911902, DOI: 10.1093/oncolo/oyad346.
- Karigyo C, Pessoa B, Nicacio S, Terwilliger E, Costa P, dos Santos P, Ernani V, Seetharam M, Murakami A, Batalini F. Cardiac Tumors: Review. Brazilian Journal Of Cardiovascular Surgery 2024, 39: e20230405. PMID: 39038269, PMCID: PMC11262154, DOI: 10.21470/1678-9741-2023-0405.
- Souza F, D’Amato G, Jonczak E, Costa P, Trent J, Rosenberg A, Yechieli R, Temple H, Pattany P, Subhawong T. MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results. Frontiers In Oncology 2023, 13: 1286807. PMID: 38188297, PMCID: PMC10766853, DOI: 10.3389/fonc.2023.1286807.
- O’Neil D, Martei Y, Crew K, Castillo B, Costa P, Lim T, Michel A, Rubin E, Goel N, Hurley J, Lopes G, Antoni M. Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open 2023, 6: e2346223. PMID: 38051529, PMCID: PMC10698616, DOI: 10.1001/jamanetworkopen.2023.46223.
- Yan C, Costa P, Wu Y. Acute pancreatitis from a delayed haemolytic transfusion reaction. Transfusion Medicine 2022, 32: 522-524. PMID: 36056461, DOI: 10.1111/tme.12912.
- Liu S, Miramontes B, Souza F, Costa P, Subhawong T, Espejo-Freire A, Jonczak E, D'Amato G, Venkat S. Cryoablation as an effective treatment for desmoid tumors: A single-institution case series. Journal Of Clinical Oncology 2022, 40: e23543-e23543. DOI: 10.1200/jco.2022.40.16_suppl.e23543.
- Costa P, Arora A, Tan H, Fernandez Y, Campoverde L, Coelho P, Bialick S, Espejo-Freire A, Jonczak E, D'Amato G, Subhawong T, Trent J. Comparative effectiveness of systemic treatments in desmoid tumors. Journal Of Clinical Oncology 2022, 40: e23534-e23534. DOI: 10.1200/jco.2022.40.16_suppl.e23534.
- Coelho P, Seldon C, Vazquez C, Yang B, Rose B, Bialick S, Espejo-Freire A, Costa P, D'Amato G, Trent J, Yechieli R, Jonczak E. Complete pathological response after neoadjuvant treatment in soft tissue sarcoma: A single-institution experience. Journal Of Clinical Oncology 2022, 40: e23526-e23526. DOI: 10.1200/jco.2022.40.16_suppl.e23526.
- Espejo-Freire A, Campoverde L, Kropotova Y, Statz-Geary K, Costa P, Coelho P, Bialick S, D'Amato G, Jonczak E, Trent J, Dhir A. Heterogeneity in treatment regimens for AYA bone sarcomas: A comparison of outcomes at a single sarcoma center. Journal Of Clinical Oncology 2022, 40: e23508-e23508. DOI: 10.1200/jco.2022.40.16_suppl.e23508.
- Coelho P, Bialick S, Rose B, Elliot A, Walker P, Abraham J, Leu K, von Mehren M, Espejo-Freire A, Costa P, D'Amato G, Rosenberg A, Trent J, Dhir A. DNA damage response pathways in synovial sarcoma. Journal Of Clinical Oncology 2022, 40: 11580-11580. DOI: 10.1200/jco.2022.40.16_suppl.11580.
- Bialick S, Statz-Geary K, Elliott A, Abraham J, Walker P, Espejo-Freire A, Coelho P, Costa P, Leu K, von Mehren M, D'Amato G, Jonczak E, Trent J, Rosenberg A, Dhir A. Pan-sarcoma analysis of DNA damage response pathway alterations and deficiency. Journal Of Clinical Oncology 2022, 40: 11548-11548. DOI: 10.1200/jco.2022.40.16_suppl.11548.
- Bialick S, Rose B, Espejo-Freire A, Coelho P, Costa P, Campoverde L, Drusbosky L, Arshad J, Serrano C, George S, Bauer S, Goel N, Venkat S, Dhir A, Jonczak E, D'Amato G, Trent J. KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor. Journal Of Clinical Oncology 2022, 40: 11514-11514. DOI: 10.1200/jco.2022.40.16_suppl.11514.
- Minjares R, Costa P, Montoya-Cerrillo D, Aguirre L. Primary jejunal gastrointestinal stromal tumor in a patient with phakomatosis: a case report of an uncommon source of massive gastrointestinal hemorrhage. Gastrointestinal Stromal Tumor 2022, 5: 2-2. DOI: 10.21037/gist-21-13.
- Barreto-Coelho P, Rosenberg A, Subhawong T, Costa P, Espejo-Freire A, Bialick S, Jonczak E, Trent J, D'Amato G. Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precision Oncology 2022, 6: e2100336. PMID: 35108034, DOI: 10.1200/po.21.00336.
- Minjares RO, Aguirre LE, Costa PA, Montoya-Cerrillo DM, Goldberg DS. Primary Jejunal GIST in a Patient with Phakomatosis: An Atypical Source of Massive Gastrointestinal Hemorrhage Associated with RASopathy. Gastrointestinal Stromal Tumor 2022. doi: 10.21037/gist-21-13
- Freire A, Elliott A, Rosenberg A, Costa P, Barreto-Coelho P, Jonczak E, D’Amato G, Subhawong T, Arshad J, Diaz-Perez J, Korn W, Oberley M, Magee D, Dizon D, von Mehren M, Khushman M, Hussein A, Leu K, Trent J. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. Cancers 2021, 13: 4816. PMID: 34638300, PMCID: PMC8507700, DOI: 10.3390/cancers13194816.
- Costa P, Espejo-Freire A, Fan K, Albini T, Pongas G. Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate. Leukemia & Lymphoma 2021, 63: 239-242. PMID: 34514943, DOI: 10.1080/10428194.2021.1978090.
- Costa P, Marbin S, Costa B, Espejo‐Freire A, Saul E, Barreto‐Coelho P, Allen A, Hakim M, Goel N, D’Amato G, Subhawong T, Trent J. A nonrandom association of breast implants and the formation of desmoid tumors. The Breast Journal 2021, 27: 768-775. PMID: 34453383, DOI: 10.1111/tbj.14276.
- Arshad J, Costa P, Barreto-Coelho P, Valdes B, Trent J. Immunotherapy Strategies for Gastrointestinal Stromal Tumor. Cancers 2021, 13: 3525. PMID: 34298737, PMCID: PMC8306810, DOI: 10.3390/cancers13143525.
- Coelho P, Costa P, Freire A, Kwon D, Jonczak E, D'Amato G, Trent J. Outcomes of metastatic synovial sarcoma with doxorubicin, pazopanib, and ifosfamide therapy. Journal Of Clinical Oncology 2021, 39: e23552-e23552. DOI: 10.1200/jco.2021.39.15_suppl.e23552.
- Hana C, Costa P, D'Amato G, Trent J. Differential risk factors between uterine sarcomas and malignant mixed Müllerian tumors. Journal Of Clinical Oncology 2021, 39: e23551-e23551. DOI: 10.1200/jco.2021.39.15_suppl.e23551.
- Dawar R, Gawri K, Rodriguez E, Kwon D, Basher F, Costa P, Khan K, Torres T, Ikpeazu C, Lopes G. Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy. Journal Of Clinical Oncology 2021, 39: e21219-e21219. DOI: 10.1200/jco.2021.39.15_suppl.e21219.
- Rodriguez E, Dawar R, Basher F, Costa P, Torres T, Nguyen D, Villamizar N, Lopes G. Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice. Journal Of Clinical Oncology 2021, 39: e20507-e20507. DOI: 10.1200/jco.2021.39.15_suppl.e20507.
- Costa P, Gallegos J, Pongas G. Outcomes in peripheral T-cell lymphomas: An analysis of patients treated at a single academic institution. Journal Of Clinical Oncology 2021, 39: e19524-e19524. DOI: 10.1200/jco.2021.39.15_suppl.e19524.
- Alasfour M, Alawadi S, AlMojel M, Costa P, Coelho P, Plate T, Ahn S, Lopes G. Clinical outcomes of cancer patients with COVID-19: A systematic review and meta-analysis. Journal Of Clinical Oncology 2021, 39: e18600-e18600. DOI: 10.1200/jco.2021.39.15_suppl.e18600.
- Costa P, Pelaez D, Tse D, Benedetto P. Neoadjuvant intraarterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma: A 33-year single-institution experience. Journal Of Clinical Oncology 2021, 39: e18051-e18051. DOI: 10.1200/jco.2021.39.15_suppl.e18051.
- Costa P, Saul E, Paul Y, Iyer S, da Silva L, Tamariz L, Lopes G. Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice 2021, 17: e629-e636. PMID: 33974815, DOI: 10.1200/op.20.00961.
- Costa P, Costa B, Rozenbaum G, Barreto-Coelho P. Anti-Ma paraneoplastic opsoclonus–myoclonus syndrome. BMJ Case Reports 2021, 14: e243136. PMID: 33975854, PMCID: PMC8117984, DOI: 10.1136/bcr-2021-243136.
- Costa P, Hana C, Balaji N, Skryd A, Valdes B, Minjares R, Barreto-Coelho P, Espejo-Freire A, Hakim M, Jonczak E, Subhawong T, Livingstone A, Trent J, D'Amato G. Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases. Gastrointestinal Stromal Tumor 2021, 4: 1-1. DOI: 10.21037/gist-21-1.
- Barreto-Coelho P, Costa P, Espejo-Freire A, Jonczak E, D’Amato G, Trent J. Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances. TouchREVIEWS In Oncology & Haematology 2021, 17: 18. DOI: 10.17925/ohr.2021.17.1.18.
- Costa PA, Hana CKA, Chakravarthy N, Skryd AF, Valdes BN, Barreto-Coelho P, Minjares RO, Espejo-Freire A, Hakim MO, Jonczak E, Subhawong T, Livingstone A, Trent JC, D’Amato GZ. Dose Escalation of Ripretinib can Lead to Response in Advanced Gastrointestinal Stromal Tumors Refractory to the Standard Dose: A Report of Two Cases. Gastrointestinal Stromal Tumor. DOI: 10.21037/gist-21-1
- Barreto-Coelho P., Costa PA, Espejo-Freire A., Jonczak E., D’Amato G., Trent J.C. Advanced and Metastatic GIST: Review of Current Knowledge and Latest Advances 2021; touchONCOLOGY.
- Costa P, Costa B, Milikowski C, St Onge J. Acute generalised exanthematous pustulosis associated with shock. BMJ Case Reports 2020, 13: e235846. PMID: 33127730, PMCID: PMC7604797, DOI: 10.1136/bcr-2020-235846.
- Costa P, Needelman B, Tjendra Y, Hoffman J. High-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a cervical mass. BMJ Case Reports 2020, 13: e235451. PMID: 32843454, PMCID: PMC7449310, DOI: 10.1136/bcr-2020-235451.
- Espejo Freire A, Costa P, Alasfour M, Akgun Y, Rosenberg A, Diaz-Perez J, Kwon D, Subhawong T, Arshad J, Trent J. Clinical behavior and treatment outcomes in angiosarcoma: A 10-year retrospective review. Journal Of Clinical Oncology 2020, 38: e23555-e23555. DOI: 10.1200/jco.2020.38.15_suppl.e23555.
- Espejo Freire A, Elliott A, Akgun Y, Costa P, Alasfour M, Rosenberg A, Diaz-Perez J, Subhawong T, Arshad J, Korn W, Dizon D, von Mehren M, Khushman M, Hussein A, Leu K, Trent J. Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients. Journal Of Clinical Oncology 2020, 38: 11545-11545. DOI: 10.1200/jco.2020.38.15_suppl.11545.
- Ferreira Junior E, Costa P, Freire Golveia Silveira L, Pertile Salvioni N, Loureiro B, Lodi Peres S, Pereira T. Transhiatal esophagectomy with gastric pull-up, pyloric exclusion and Roux-en-Y gastroenterostomy for the management of esophageal caustic injury. International Journal Of Surgery Case Reports 2019, 56: 66-69. PMID: 30831510, PMCID: PMC6403175, DOI: 10.1016/j.ijscr.2019.02.006.
- Ferreira Junior E, Costa P, Silveira L, Almeida L, Salvioni N, Loureiro B. Giant bullous emphysema mistaken for traumatic pneumothorax. International Journal Of Surgery Case Reports 2019, 56: 50-54. PMID: 30826593, PMCID: PMC6402233, DOI: 10.1016/j.ijscr.2019.02.005.
- Costa P, Reis W, Loureiro B, Ferreira E, Rocha J, Alencar K. Tumor Desmoplásico de Pequenas Células Redondas: Relato de Caso. Revista Brasileira De Cancerologia 2018, 64: 575-579. DOI: 10.32635/2176-9745.rbc.2018v64n4.208.
- Ferreira Junior E, Apolinario Costa P, Freire Golveia Silveira L, Valois Vieira R, Lima Martins Soares H, Menon Loureiro B, Pertile Salvioni N, Coelho Ferreira Rocha J. Localized pancreatic Castleman disease presenting with extrahepatic dilatation of bile ducts: A case report and review of published cases. International Journal Of Surgery Case Reports 2018, 54: 28-33. PMID: 30513495, PMCID: PMC6279997, DOI: 10.1016/j.ijscr.2018.11.006.
- Desmoplastic small-round-cell tumorCosta PA, Reis WG, Loureiro BM, Ferreira Junior EG, Rocha JRCF, Alencar KMSA. Revista Brasileira De Cancerologia, 2018, Dec; 64(4), 573-577.
Departments and Programs
Locations
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511